The regulatory approval marks a significant milestone for the firm, which confirmed that the ophthalmic drug will reach eligible patients across the United States before the end of the year. Investors responded sharply to the news, driving the stock upward throughout the session as trading volume fluctuated following the resumption of activity after the afternoon pause.
In section Market Quotes
Outlook Therapeutics Shares Surge After FDA Approves Lytenava
A 21% jump in share price greeted the Food and Drug Administration’s decision to greenlight Lytenava, a treatment for neovascular age-related macular degeneration. The stock climbed to $1.60 on Friday, briefly touching $1.75 before a temporary trading halt triggered a slight correction in the market's initial enthusiasm.
Comments (0)
No comments yet. Be the first!